The 37TrillionCells Initiative
37,000,000,000,000
Mission
Implement and operate a novel multidisciplinary, muti-institutional research initiative for the development of Cell-Based Interception Medicine, where researchers are developing and characterizing a series of iPSCs and organoid models recreating the development of the normal brain cells as well as that of neurodegenerative diseases. Single-Cell Proteomics (SCP) is used to profile the proteome of each cell type at single-cell resolution to follow specific gene expression programs and identify targets for the discovery of drugs that can reprogram gene expression and help to cure diseases.
About
37TrillionCells
Cell-based Interceptive Medicine
Active Projects
Annual Meeting
Contact
About 37TrillionCells
Over the past few years, single-cell genomics has revolutionized biology and medicine to a point where knowledge on some biological systems and disease had to be consequently replaced. Classical methods that measure RNA, protein, DNA and other cell components in populations of cells generate results that are the average of what is found in many different cells, masking the effects that occur at the individual cell level that are often crucial. Conversely, single-cell (sc) technologies capture these differences. The development of multimodal methods that couple leading-edge procedures of genomics, epigenomics and proteomics at the sc level is the essence of the 37TrillionCells Initiative.
Cell-based Interceptive Medicine
Cell-based Interceptive Medicine is a new medical paradigm first launched in Europe - more than 100 institutions are participating in a large-scale project called Lifetime, funded by the European Union - which aims to develop and use omics technologies (genomics, transcriptomics, proteomics, etc.) at single-cell resolution to early detect molecular disturbances that can lead to disease and develop treatments before tissue damage and symptoms are present. To join this movement, the 37TrillionCells initiative was launched. Its mission is to improve healthcare by advancing the integration of omics to map gene expression programs at cellular resolution.
Active Projects
-
Towards Cell-based Interceptive Medicine: Combining proteome profiling and phage display to track the phenotypic trajectory of cells during diabetes (funded by the Ministry of Economy and Innovation (MEI)-IRCM strategic initiative)
Investigators: Benoit Coulombe with Jennifer Estall, Mathieu Ferron, Mohan Malleshaiah, Rémi Rabasa-Lhoret -
Towards a medical paradigm shift: Cell-based Interceptive Medicine (funded by the Winnermax Venture Capital)
Investigator: Benoit Coulombe
Annual Meeting
The next 37TrillionCells meeting will take place in 2024. The exact date and format will be released soon.
Contact
Benoit Coulombe, PhD
Dr. Benoit Coulombe is director of the Translational Proteomics Laboratory at the Institut de Recherches Cliniques de Montréal
